KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2026)

Takeda Pharmaceutical has reported Total Liabilities over the past 9 years, most recently at $49.0 billion for Q1 2026.

  • For Q1 2026, Total Liabilities rose 2.15% year-over-year to $49.0 billion; the TTM value through Mar 2026 reached $49.0 billion, up 2.15%, while the annual FY2026 figure was $51.0 billion, 6.26% up from the prior year.
  • Total Liabilities was $49.0 billion for Q1 2026 at Takeda Pharmaceutical, up from $47.9 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $64.5 billion in Q1 2022 and bottomed at $47.9 billion in Q1 2025.
  • The 5-year median for Total Liabilities is $52.9 billion (2024), against an average of $54.3 billion.
  • Year-over-year, Total Liabilities dropped 11.75% in 2022 and then rose 2.15% in 2026.
  • Over 5 years, Total Liabilities stood at $64.5 billion in 2022, then decreased by 10.87% to $57.5 billion in 2023, then fell by 8.02% to $52.9 billion in 2024, then fell by 9.34% to $47.9 billion in 2025, then increased by 2.15% to $49.0 billion in 2026.
  • The last three reported values for Total Liabilities were $49.0 billion (Q1 2026), $47.9 billion (Q1 2025), and $52.9 billion (Q1 2024) per Business Quant data.